KYTHERA Biopharmaceuticals (KYTH) to Release Earnings on Thursday

Share on StockTwits

KYTHERA Biopharmaceuticals (NASDAQ:KYTH) is scheduled to be posting its quarterly earnings results on Thursday, August 7th. Individual interested in registering for the company’s earnings conference call can do so using this link.

KYTHERA Biopharmaceuticals (NASDAQ:KYTH) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($3.18) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.67) by $2.51. On average, analysts expect KYTHERA Biopharmaceuticals to post $-3.33 EPS for the current fiscal year and $-2.64 EPS for the next fiscal year.

KYTHERA Biopharmaceuticals (NASDAQ:KYTH) opened at 34.56 on Wednesday. KYTHERA Biopharmaceuticals has a 1-year low of $23.03 and a 1-year high of $56.36. The stock’s 50-day moving average is $35.68 and its 200-day moving average is $38.92. The company’s market cap is $783.0 million.

In other KYTHERA Biopharmaceuticals news, CEO Keith R. Leonard sold 1,828 shares of the company’s stock on the open market in a transaction that occurred on Monday, August 4th. The stock was sold at an average price of $35.10, for a total transaction of $64,162.80. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

KYTHERA Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of prescription products for the aesthetic medicine market.

Receive News & Ratings for KYTHERA Biopharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KYTHERA Biopharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.

Latest News

Washington Real Estate Investment Trust Given Consensus Rating of “Hold” by Brokerages
Washington Real Estate Investment Trust Given Consensus Rating of “Hold” by Brokerages
Qunar Cayman Islands Receives Consensus Rating of “Buy” from Analysts
Qunar Cayman Islands Receives Consensus Rating of “Buy” from Analysts
Neurocrine Biosciences Given Average Rating of “Buy” by Brokerages
Neurocrine Biosciences Given Average Rating of “Buy” by Brokerages
Astoria Financial Corp Given Consensus Recommendation of “Hold” by Analysts
Astoria Financial Corp Given Consensus Recommendation of “Hold” by Analysts
KBR Receives Average Recommendation of “Buy” from Analysts
KBR Receives Average Recommendation of “Buy” from Analysts
Vanguard Natural Resources Given Consensus Recommendation of “Hold” by Analysts
Vanguard Natural Resources Given Consensus Recommendation of “Hold” by Analysts


Leave a Reply

 
Advertisement
Advertisement
© 2006-2014 Mideast Time.